4.6 Article

Lorlatinib for advanced ROS1+non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

期刊

ESMO OPEN
卷 7, 期 2, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.esmoop.2022.100418

关键词

NSCLC; ROS1; chemotherapy; brain metastases

类别

资金

  1. French Thoracic Cancer Intergroup (IFCT) - Pfizer

向作者/读者索取更多资源

This study investigates the efficacy and safety of lorlatinib in patients with ROS1-rearranged non-small-cell lung cancer (ROS1thorn NSCLC) treated through an expanded access program. The results suggest that lorlatinib is a major treatment option for advanced refractory ROS1thorn NSCLC in the treatment strategy.
Introduction: ROS1-rearranged (ROS1thorn) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and real-world data are lacking. We investigate the efficacy and safety of lorlatinib, a third-generation TKI targeting ALK and ROS1, in patients with ROS1thorn NSCLC treated through an expanded access program. Methods: Consecutive patients with advanced ROS1thorn NSCLC treated with lorlatinib between October 2015 and June 2019 were included. Data were collected from medical records. The primary endpoint was progression-free survival. Results: Out of the 80 patients included, 47(59%) were female, 49(62%) never smokers (less than 100 cigarettes over the lifetime), and 68(85%) had stage IV NSCLC at diagnosis. Most frequent histology was adenocarcinoma (95%) and median age was 58.2 years. At the time of lorlatinib initiation, 51(64%) patients had brain metastases and 55(81%) were PS 0-1. Lorlatinib was administered as second/third/fourth/fifththorn line in 29%/28%/18%/ 26% of patients. All patients previously received at least one ROS1 TKI, and 55(69%) previously received chemotherapy. Median follow-up from lorlatinib initiation was 22.2 months. Median progression-free survival and overall survival from lorlatinib initiation were 7.1 months [95% confidence interval (CI) 5.0-9.9 months] and 19.6 months (95% CI 12.3-27.5 months). Median duration of treatment with lorlatinib was 7.4 months (95% CI 6.5-13.1 months). Overall response and disease control rates were 45% and 82%, respectively. The central nervous system response rate was 72%. Treatment was stopped due to toxicity in 10 patients (13%). The safety profile was consistent with previously published data. Conclusions: Lorlatinib is a major treatment option for advanced refractory ROS1thorn NSCLC in treatment strategy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据